Back

Kirkland Advises GTCR on Strategic Majority Investment in Biocoat

Kirkland & Ellis advised GTCR on its strategic, majority investment in Biocoat Holdings, LLC (Biocoat), a leading medical device contract manufacturing organization. As part of its Leaders Strategy™ to find and partner with management leaders in core domains to identify, acquire and build market-leading companies through organic growth and strategic acquisitions, GTCR will partner with industry veteran Chip Hance, the current Chairman of GTCR portfolio company Regatta Medical Holdings, LLC (d/b/a Resonetics), who will join Biocoat as Executive Chairman. Going forward, the existing Biocoat management team, led by CEO Jim Moran, will continue in their existing roles executing on Biocoat’s growth initiatives in partnership with GTCR.

LEGAL DESIRE NEWSLETTER

Where the legal industry reads first.

Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.

No spam. Unsubscribe anytime.

From Legal Desire

Is your firm the one being cited, or the one being skipped?

We ran the test. On several everyday legal questions, software companies are answering and law firms are not. We help firms fix that, and we build the technology behind the practice.

Legal Desire Press
https://legaldesire.com/about-us/
Our editorial team that covers judgments, deals, law firm updates, careers and policy across the globe. Coverage is editorially independent; sponsored posts are labeled Partner Content.

Leave a Reply

Your email address will not be published. Required fields are marked *